[{"address1": "177 East Colorado Boulevard", "address2": "Suite 700", "city": "Pasadena", "state": "CA", "zip": "91105", "country": "United States", "phone": "626 304 3400", "fax": "626 304 3401", "website": "https://arrowheadpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.", "fullTimeEmployees": 711, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher R. Anzalone Ph.D.", "age": 56, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2025, "totalPay": 2219569, "exercisedValue": 2948360, "unexercisedValue": 1465915}, {"maxAge": 1, "name": "Dr. Vincent  Anzalone CFA", "title": "Head of Investor Relations & VP", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Lovy", "title": "Director of Communications", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bruce D. Given M.D.", "age": 71, "title": "Chief Medical Scientist", "yearBorn": 1954, "fiscalYear": 2025, "totalPay": 486308, "exercisedValue": 5934362, "unexercisedValue": 6159876}, {"maxAge": 1, "name": "Dr. Mark  Seefeld", "age": 71, "title": "Head of Toxicology & VP", "yearBorn": 1954, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Aaron  Tan", "title": "Head of Tax", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy  Davis M.B.A.", "title": "SVP of Cardiovascular & Head of Metabolic Franchise", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nadia  Meshkova M.B.A.", "title": "VP & Treasurer", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 3, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1768176000, "compensationAsOfEpochDate": 1767139200, "irWebsite": "http://www.arrowheadresearch.com/invest.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 69.12, "open": 70.15, "dayLow": 67.835, "dayHigh": 72.0, "regularMarketPreviousClose": 69.12, "regularMarketOpen": 70.15, "regularMarketDayLow": 67.835, "regularMarketDayHigh": 72.0, "payoutRatio": 0.0, "beta": 1.218, "forwardPE": -15.792711, "volume": 2865865, "regularMarketVolume": 2865865, "averageVolume": 2660645, "averageVolume10days": 1759610, "averageDailyVolume10Day": 1759610, "bid": 68.72, "ask": 70.92, "bidSize": 13, "askSize": 13, "marketCap": 9706941440, "fiftyTwoWeekLow": 9.57, "fiftyTwoWeekHigh": 76.76, "allTimeHigh": 2925.0, "allTimeLow": 1.2, "priceToSalesTrailing12Months": 11.702893, "fiftyDayAverage": 62.6046, "twoHundredDayAverage": 32.968723, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 9279555584, "profitMargins": -0.0019699999, "floatShares": 117529591, "sharesOutstanding": 140010690, "sharesShort": 10790834, "sharesShortPriorMonth": 10234550, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0759, "heldPercentInsiders": 0.03805, "heldPercentInstitutions": 0.82531, "shortRatio": 4.02, "shortPercentOfFloat": 0.10520001, "impliedSharesOutstanding": 140010690, "bookValue": 3.434, "priceToBook": 20.189283, "lastFiscalYearEnd": 1759190400, "nextFiscalYearEnd": 1790726400, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -1631000, "trailingEps": -0.01, "forwardEps": -4.39, "lastSplitFactor": "1:10", "lastSplitDate": 1321488000, "enterpriseToRevenue": 11.188, "enterpriseToEbitda": 75.891, "52WeekChange": 2.6883671, "SandP52WeekChange": 0.16255379, "quoteType": "EQUITY", "currentPrice": 69.33, "targetHighPrice": 110.0, "targetLowPrice": 35.0, "targetMeanPrice": 81.91667, "targetMedianPrice": 82.5, "recommendationMean": 1.76923, "recommendationKey": "buy", "numberOfAnalystOpinions": 12, "totalCash": 917465984, "totalCashPerShare": 6.756, "ebitda": 122274000, "totalDebt": 743980992, "quickRatio": 4.728, "currentRatio": 4.863, "totalRevenue": 829448000, "debtToEquity": 147.787, "revenuePerShare": 6.201, "returnOnAssets": 0.04868, "returnOnEquity": 0.08672, "grossProfits": 829448000, "freeCashflow": 96153624, "operatingCashflow": 179552000, "grossMargins": 1.0, "ebitdaMargins": 0.14741999, "operatingMargins": 0.17197001, "financialCurrency": "USD", "symbol": "ARWR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NMS", "messageBoardId": "finmb_203142", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.3038181, "regularMarketPrice": 69.33, "shortName": "Arrowhead Pharmaceuticals, Inc.", "longName": "Arrowhead Pharmaceuticals, Inc.", "corporateActions": [], "postMarketTime": 1769818944, "regularMarketTime": 1769806801, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 756052200000, "postMarketChangePercent": -1.341411, "postMarketPrice": 68.4, "postMarketChange": -0.9300003, "regularMarketChange": 0.20999908, "regularMarketDayRange": "67.835 - 72.0", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2660645, "fiftyTwoWeekLowChange": 59.760002, "fiftyTwoWeekLowChangePercent": 6.2445145, "fiftyTwoWeekRange": "9.57 - 76.76", "fiftyTwoWeekHighChange": -7.4300003, "fiftyTwoWeekHighChangePercent": -0.09679521, "fiftyTwoWeekChangePercent": 268.8367, "earningsTimestamp": 1770325200, "earningsTimestampStart": 1770325200, "earningsTimestampEnd": 1770325200, "earningsCallTimestampStart": 1770327000, "earningsCallTimestampEnd": 1770327000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.01, "epsForward": -4.39, "epsCurrentYear": -3.30909, "priceEpsCurrentYear": -20.95138, "fiftyDayAverageChange": 6.725403, "fiftyDayAverageChangePercent": 0.10742666, "twoHundredDayAverageChange": 36.36128, "twoHundredDayAverageChangePercent": 1.1029022, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "displayName": "Arrowhead Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2026-01-31"}]